Drug Design, Development and Therapy
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 6.1 | Q1 | 88.2% | 1.309 | Q1 | 89.7% |
| 2024 | 5.1 | Q1 | 87.8% | 1.190 | Q1 | 88.3% |
| 2023 | 4.7 | Q1 | 84.8% | 0.999 | Q1 | 85.5% |
| 2022 | 4.8 | Q1 | 81.1% | 0.887 | Q1 | 83.4% |
| 2021 | 4.3 | Q2 | 72.5% | 0.784 | Q1 | 80.6% |
| 2020 | — | — | 0.964 | Q1 | 84.6% | |
| 2019 | — | — | 0.880 | Q1 | 82.7% | |
| 2018 | — | — | 0.986 | Q1 | 83.8% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
ISSN
1177-8881
country
NZcoverage
2007-2026